Programmed cell death 1 genetic variant and liver damage in nonalcoholic fatty liver disease

Abstract Background and Aims Programmed cell death 1/programmed cell death‐ligand 1 (PD‐1/PDL‐1) axis has been reported to modulate liver inflammation and progression to hepatocellular carcinoma (HCC) in patients with nonalcoholic fatty liver disease (NAFLD). Here, we examined whether the PDCD1 variation is associated with NAFLD severity in individuals with liver biopsy. Methods We examined the impact of PDCD1 gene variants on HCC, as robust severe liver disease phenotype in UK Biobank participants. The strongest genetic association with the rs13023138 G>C variation was subsequently tested for association with liver damage in 2889 individuals who underwent liver biopsy for suspected nonalcoholic steatohepatitis (NASH). Hepatic transcriptome was examined by RNA‐Seq in a subset of NAFLD individuals ( n = 121). Transcriptomic and deconvolution analyses were performed to identify biological pathways modulated by the risk allele. Results The rs13023138 C>G showed the most robust association with HCC in UK Biobank ( p = 5.28E‐4, OR = 1.32, 95% CI [1.1, 1.5]). In the liver biopsy cohort, rs13023138 G allele was independently associated with severe steatosis (OR 1.17, 95% CI 1.02‐1.34; p = .01), NASH (OR 1.22, 95% CI 1.09‐1.37; p < .001) and advanced fibrosis (OR 1.26, 95% CI 1.06‐1.50; p = .007). At deconvolution analysis, rs13023138 G>C allele was linked to higher hepatic representation of M1 macrophages, paralleled by upregulation of pathways related to inflammation and higher expression of CXCR6. Conclusions The PDCD1 rs13023138 G allele was associated with HCC development in the general population and with liver disease severity in patients at high risk of NASH.